Results
Piramal Pharma Q2 FY27 Standalone Profit Rises 50%
Piramal Pharma's Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, ending September 30, 2026.
Standalone Q2 net profit rose 50.4% QoQ to ₹170.74 crore on reven
